Cogent Biosciences Cultura da Companhia

Andy is an accomplished executive with extensive commercial, development, and strategic leadership experience during a 20-year career in the pharmaceutical industry, with a specific focus on oncology and hematology products. Before joining Cogent as President & CEO, he served at Array Biopharma as the Chief Operating Officer until its acquisition by Pfizer in 2019. At Array, he was responsible for leading the sales, marketing, manufacturing, and corporate strategy teams, culminating in the successful commercialization of Mektovi and Braftovi for the treatment of BRAF mutant metastatic melanoma. Prior to working at Array, Andy held management positions at both Hospira, Inc., a global pharmaceutical and medical device company, and Pfizer, Inc. as part of its Oncology business unit. Andy currently serves on the Board of Directors for Harpoon Therapeutics (Nasdaq: HARP) and Turmeric Acquisition Corporation (Nasdaq: TMPMU). He holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor’s degree from Swarthmore College. In his spare time, Andy enjoys hiking and skiing with his wife and kids.